Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2121)	1/14/2008 1:52:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ZGEN traded earlier today above last Tuesday's H of $12.69 & is still up 4.09% with volume above its ADV. bigcharts.marketwatch.com Its CEO, Bruce L.A. Carter, Ph.D.,is scheduled to present at the Stanford Group Company Annual Healthcare Conference in Washington, D.C. on Thursday. On Tuesday, was when it announced that it has initiated a PII of IL-21 in combination with Nexavar (sorafenib) tablets in patients with advanced renal cell cancer. In the PI of IL-21 in combination with Nexavar in patients with renal cell cancer,which were presented in Oct at the AACR Conference,the data indicated that the combination was well tolerated,& evidence of anti-tumor activity was documented in the majority of the patients. ZGEN insiders reportedly hold > 45% & it also has a good institutional following.<g> finance.yahoo.com The short position came down some in the last month, but is still > 15x its ADV. ZGEN needs to close above its Dec H of $15.16 in order to get off from the DT coming from its Jan2006 H at $16.63 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2121)	2/4/2008 11:02:41 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SGP Is trying to get above the $21 level. Volume is now > 4.7M bigcharts.marketwatch.com It announced today that the FDA has approved its ASMANEX TWISTHALER 110 mcg for treatment of asthma as a preventive therapy in patients 4 to 11 years of age. (The 220 mcg was approved on Mar 2005 for treatment in patients > 11 years of age.) Of course, the Vitorin problems will affect SGP > MRK & SGP has now a good amount of resistance at the $25 level. bigcharts.marketwatch.com Bernard